{
  "id": "601d6a651cb411341a000031",
  "type": "list",
  "question": "Please list the 2 vaccines for herpes zoster(shingles)",
  "ideal_answer": "live attenuated zoster vaccine (Zostavax\u00ae) and live attenuates herpes zoster (Shingles) are effective for treatment of infections with herpesZoster(shingles).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31015813",
    "http://www.ncbi.nlm.nih.gov/pubmed/30558674",
    "http://www.ncbi.nlm.nih.gov/pubmed/31436592",
    "http://www.ncbi.nlm.nih.gov/pubmed/32284271",
    "http://www.ncbi.nlm.nih.gov/pubmed/29457489",
    "http://www.ncbi.nlm.nih.gov/pubmed/20113211",
    "http://www.ncbi.nlm.nih.gov/pubmed/32305975",
    "http://www.ncbi.nlm.nih.gov/pubmed/30179221",
    "http://www.ncbi.nlm.nih.gov/pubmed/22024532",
    "http://www.ncbi.nlm.nih.gov/pubmed/32999027",
    "http://www.ncbi.nlm.nih.gov/pubmed/23839657",
    "http://www.ncbi.nlm.nih.gov/pubmed/25144544",
    "http://www.ncbi.nlm.nih.gov/pubmed/16977285",
    "http://www.ncbi.nlm.nih.gov/pubmed/28426274",
    "http://www.ncbi.nlm.nih.gov/pubmed/31339679",
    "http://www.ncbi.nlm.nih.gov/pubmed/33294953",
    "http://www.ncbi.nlm.nih.gov/pubmed/29720364",
    "http://www.ncbi.nlm.nih.gov/pubmed/31061027",
    "http://www.ncbi.nlm.nih.gov/pubmed/24834646",
    "http://www.ncbi.nlm.nih.gov/pubmed/17326312",
    "http://www.ncbi.nlm.nih.gov/pubmed/27189459",
    "http://www.ncbi.nlm.nih.gov/pubmed/22086893"
  ],
  "snippets": [
    {
      "text": "Shingrix is a\u00a0recombinant adjuvant subunit vaccine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33294953",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Two different vaccines have been developed to prevent HZ; one is based on a live attenuated VZV strain (Zostavax), and the other is based on adjuvanted gE recombinant protein (Shingrix).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32999027",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "HZ prophylaxis has been strongly recommended in older adults through vaccination with a live attenuated vaccine, Zostavax\u00ae. A new recombinant subunit vaccine, HZ/su (Shingrix\u00ae), is the subject of this review. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31339679",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": ": HZ/su is a new adjuvanted recombinant vaccine approved by the Food and Drug Administration for the prevention of herpes zoster in adults 50 years of age and older. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29457489",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "o review current evidence and develop guidance on whether the previously authorized LZV (Zostavax\u00ae) and/or the recently authorized RZV (Shingrix\u00ae) vaccine should be offered to Canadians 50 years of age and older",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31015813",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "wo HZ vaccines are currently authorized for use in those 50 years of age and older in Canada: a live attenuated zoster vaccine (LZV) authorized in 2008; and a recombinant subunit vaccine (RZV) authorized in October 2017.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31015813",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Both vaccines have been shown to be safe and immunogenic and to reduce the incidence of HZ and post-herpetic neuralgia. Vaccine efficacy of LZV against HZ decreases with age at, and time since vaccination. The vaccine efficacy of RZV remains higher and appears to decline more slowly than vaccine efficacy of LZV across all age groups. Both vaccines are cost-effective in those 50 years of age and older compared with no vaccination, especially in those 65-79 years of age. RZV is more cost-effective than LZV.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31015813",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " live attenuated herpes zoster vaccine (ZVL) in Australia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32284271",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "his new vaccine, which combines a single VZV glycoprotein (gE) and a multicomponent adjuvant, is superior to the previously available live attenuated VZV vaccine. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32305975",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "recommending vaccination of adults 70 years of age (YOA) with the zoster vaccine live (ZVL), the only vaccine available at the time. The recently approved adjuvanted recombinant zoster vaccine (RZV) has a substantially different clinical profile that may offer additional benefits.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31061027",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Under the model assumptions, RZV is predicted to avert more HZ and PHN cases compared with ZVL. Results were robust under different scenario and sensitivity analyses.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31061027",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The recombinant zoster vaccine (Shingrix) was approved to help combat the incidence of shingles in patients age 50 years and older and the CDC now recommends it over the zoster vaccine live (Zostavax). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31436592",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: Zostavax, a live attenuated vaccine, has been approved in the United States for use in older individuals to reduce the risk and severity of herpes zoster (HZ), also known a",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22024532",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The live, attenuated shingles (herpes zoster) vaccine Zostavax(\u00ae) is approved in the EU for use in the prevention of herpes zoster and postherpetic neuralgia in adults aged \u226550 years. In",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23839657",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: A new recombinant subunit vaccine for herpes zoster (HZ or shingles) was approved by the United States Food and Drug Administration on October 20, 2017 and is expected to replace the previous live attenuate",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29720364",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A live attenuated varicella-zoster vaccine (Zostavax--Merck) has been approved by the FDA for prevention of herpes zoster (HZ; zoster; shingles) in persons > or = 60 years old. Ea",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16977285",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A live attenuated vaccine to prevent herpes zoster, or shingles (Zostavax; Merck & Co Inc, Whitehouse Station, NJ), is approved by the US Food and Drug Administration (FDA) for use in adults aged 50 years or older. Studi",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086893",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The authors characterized differences in the immunologic responses induced by two HZ vaccines, the live attenuated zoster vaccine (ZV) and the more recently developed adjuvanted varicella-zoster virus (VZV) glycoprotein E (gE) subunit herpes zoster vaccine (HZ/su), in vaccine-naive subjects and those previously vaccinated with HZ.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30179221",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Zostavax, a live attenuated vaccine against shingles (herpes zoster) has been available in Switzerland since 2008.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24834646",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A live attenuated varicella-zoster vaccine (Zostavax--Merck) has been approved by the FDA for prevention of herpes zoster (HZ; zoster; shingles) in persons > or = 60 years old.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16977285",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A critical appraisal of 'Shingrix', a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28426274",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The authors characterized differences in the immunologic responses induced by two HZ vaccines, the live attenuated zoster vaccine (ZV) and the more recently developed adjuvanted varicella-zoster virus (VZV) glycoprotein",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30179221",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The observed differences in responses paralleled the observed clinical protection of the two zoster vaccines, with HZ/su being superior to HZ.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30179221",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In order to clarify the value of each vaccine, de Boer and colleagues compare the cost-effectiveness of no vaccination, and of vaccination with Zostavax or the herpes zoster subunit vaccine in four cohorts of older adults from the perspective of the Netherlands.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30558674",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The recently available adjuvanted herpes zoster subunit vaccine Shingrix",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30558674",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The herpes zoster subunit vaccine is more efficacious than Zostavax, and it can be administered to immunosuppressed individuals.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30558674",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A live-attenuated vaccine, Zostavax is not free of limitations, which include a relatively low efficacy that wanes over time and its contraindication among immunocompromised individuals.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30558674",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Herpes zoster vaccine (Zostavax [Merck & Co., Inc.]) was licensed in 2006 and recommended by the Advisory Committee on Immunization Practices (ACIP) in 2008 for prevention of herpes zoster (shingles) and its complications among adults aged \u226560 years.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25144544",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The live, attenuated shingles (herpes zoster) vaccine Zostavax(\u00ae) is approved in the EU for use in the prevention of herpes zoster and postherpetic neuralgia in adults aged \u226550 years.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23839657",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Shingles (Herpes Zoster) Vaccine (Zostavax(\u00ae)): A Review in the Prevention of Herpes Zoster and Postherpetic Neuralgia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27189459",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Zostavax(\u00ae) is a live attenuated shingles (herpes zoster) vaccine approved in the EU for the prevention of herpes zoster (HZ) and postherpetic neuralgia (PHN) in adults aged \u226550 years.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27189459",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Shingles (herpes zoster) vaccine (zostavax(\u00ae)): a review of its use in the prevention of herpes zoster and postherpetic neuralgia in adults aged \u226550 years.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23839657",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Herpes zoster vaccine (Zostavax).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16977285",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A new vaccine called Zostavax is available to reduce the risk of shingles (herpes zoster) in people ages 60 and older.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17326312",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " immunocompetent adults. The live attenuated zoster vaccine (Zostavax, Merck & Co., Inc.) is effective in preventing shingles in individuals 60 years of age and older and recommended by the Center for Disease Control's (CDC) Advisory Committee for Immunization Practices (ACIP).AREAS COVERED IN THIS REVIEW: Literature related to the live attenuated zoster vaccine is reviewed from its beginnings in the early 1970s through to the present.WHAT THE READER WILL GAIN: Background information on herpes zoster and up to date information on the live ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20113211",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "HZ/Su is the first subunit vaccine developed to protect against shingles.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28426274",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "live attenuated vaccine, Zostervax, LZV, ZVL, HZ, adjuvated recombinant vaccine, Shingrix, RZV, hz/su"
}